EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A real‐life pilot study of the clinical application of pharmacogenomics testing on saliva in epilepsy

Antonella Riva iD, Roberta Roberti, Gianluca D'Onofrio iD, Maria Stella Vari, Elisabetta Amadori, Valentina De Giorgis iD, Caterina Cerminara, Nicola Specchio iD, Nicola Pietrafusa, Mario Tombini iD, Giovanni Assenza iD, Silvia Cappanera und 6 weitere

Epilepsia Open · 2023

DOI: 10.1002/epi4.12717 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, 2023. Verfasst von Antonella Riva und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Response to antiseizure medications (ASMs) can be influenced by several gene polymorphisms, causing either lower efficacy or higher occurrence of adverse drug reactions (ADRs). We investigated the clinical utility of salivary pharmacogenomic testing on epilepsy patients. A commercialized pharmacogenomic salivary test was performed in a cohort of epileptic patients. Genetic variants on five genes (i.e., CYP1A2 , CYP2C9 , CYP2C19 , EPHX1 , and ABCB1 ) involved in common ASMs metabolism were selected. Twenty‐one individuals (median age [Q 1 –Q 3 ]: 15 [6.5–28] years) were enrolled. Six patients harboring the homozygous *1F allele in CYP1A2 could have reduced chance of response to stiripentol due to fast metabolism. CYP2C9 had reduced activity in 10 patients (alleles * 2 and * 3 ), potentially affecting phenytoin (PHT), phenobarbital (PB), primidone, lacosamide (LCM), and valproic acid metabolism. Seven patients, carrying the *2 allele of CYP2C19 , had an increased risk of ADRs with clobazam (CLB), PB, PHT, LCM, brivaracetam; while one individual with the *17 allele in heterozygosity reported a CLB fast metabolism. Six patients showed a CC polymorphism of EPHX1 associated with the impaired efficacy of carbamazepine. ABCB1 polymorphisms related to drug‐resistance (3435 CC) or drug‐sensitive phenotype (CT or TT) were found in 6 out of 7 patients. Pharmacogenomic testing on saliva proved easy and safe in clinical practice to convey information for the management of epileptic patients, especially those resistant to treatment or sensitive to severe ADRs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsEpilepsyHumansPharmacogeneticsCytochrome P-450 CYP1A2Cytochrome P-450 CYP2C19Pilot ProjectsCytochrome P-450 CYP2C9SalivaPhenytoinClobazamPhenobarbital

Stichwörter der Autor:innen

antiseizure medicationsepilepsypharmacogenomicsprecision medicine

Substanzen

AnticonvulsantsCytochrome P-450 CYP1A2Cytochrome P-450 CYP2C19Cytochrome P-450 CYP2C9PhenytoinClobazamPhenobarbital

Autor:innen und Institutionen

  • Department of Neurosciences Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy.
  • Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto "Giannina Gaslini", Genoa, Italy.
  • Science of Health Department, University Magna Grecia of Catanzaro, Catanzaro, Italy.
  • Department of Child Neurology and Psychiatry, IRCCS Mondino Foundation, Pavia, Italy.
  • Pediatric Neurology Unit, Department of Neurosciences, Tor Vergata University of Rome, Rome, Italy.
  • Rare and Complex Epilepsy Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

ORCID-Profile: Antonella Riva, Gianluca D'Onofrio, Valentina De Giorgis, Nicola Specchio, Mario Tombini, Giovanni Assenza, Carla Marini, Emilio Russo, Pasquale Striano

Zitieren

APA

Riva, A., Roberti, R., D'Onofrio, G., Vari, M. S., Amadori, E., De Giorgis, V., Cerminara, C., Specchio, N., Pietrafusa, N., Tombini, M., Assenza, G., Cappanera, S., Marini, C., Rasmini, P., Veggiotti, P., Zara, F., Russo, E., & Striano, P. (2023). A real‐life pilot study of the clinical application of pharmacogenomics testing on saliva in epilepsy. Epilepsia Open. https://doi.org/10.1002/epi4.12717

Vancouver

Riva A, Roberti R, D'Onofrio G, Vari MS, Amadori E, De Giorgis V, et al. A real‐life pilot study of the clinical application of pharmacogenomics testing on saliva in epilepsy. Epilepsia Open. 2023. doi:10.1002/epi4.12717

BibTeX
@article{Riva2023,
  author = {Riva, Antonella and Roberti, Roberta and D'Onofrio, Gianluca and Vari, Maria Stella and Amadori, Elisabetta and De Giorgis, Valentina and Cerminara, Caterina and Specchio, Nicola and Pietrafusa, Nicola and Tombini, Mario and Assenza, Giovanni and Cappanera, Silvia and Marini, Carla and Rasmini, Paolo and Veggiotti, Pierangelo and Zara, Federico and Russo, Emilio and Striano, Pasquale},
  title = {A real‐life pilot study of the clinical application of pharmacogenomics testing on saliva in epilepsy},
  journal = {Epilepsia Open},
  year = {2023},
  doi = {10.1002/epi4.12717}
}
Kostenlos starten →